Cell and gene therapies and mRNA development and manufacturing
Cell and gene therapies are poised to serve a global patient population. However, companies working in this space face challenges in terms of supply chain complexity. The close proximity of manufacturing to patients is key for the success of many cell and gene therapies.
As part of our global network of manufacturing sites, our facility in Geleen in the Netherlands helps you overcome this challenge. The site provides flexible capacity and serves customers who need a European manufacturing footprint.
We have significant expertise in cell and gene therapy manufacturing having supported a number of commercial autologous cell therapy products in Europe. We are committed to using our expertise to help you develop and commercialize your products quickly and efficiently, so that you can ultimately deliver therapy to patients in need of treatment. Since 2021 we have also implemented mRNA / LNP technology on site.
A full range of services in the heart of Europe
We offer a full range of development and manufacturing services for cell and gene therapies. Our experience covers many cell types including T-cells, dendritic cells, pluripotent stem cells and mesenchymal stem cells. We can provide tailored support at all stages, from process development to first-in-human trials and commercial production.
European cell and gene therapy manufacturing
With world-class expertise and customizable services, our sites in the Netherlands can help you develop and commercialize your cell and gene therapy products.
Unique expertise
Through our experience in manufacturing cell therapy products in Europe, we are well-placed to help you in your commercialization journey. Our expertise allows us to offer several release bioassays in-house, shortening your timelines for manufacture, testing and release. We also provide regulatory affairs consultancy and support.